936727-74-1

Usage

General Description

1-bromo-4-(2-(methylsulfonyl)ethyl)benzene is an organic compound with the chemical formula C10H13BrO2S. It is a substituted benzene derivative with a bromine atom at the 1-position and a 2-(methylsulfonyl)ethyl group at the 4-position. 1-bromo-4-(2-(methylsulfonyl)ethyl)benzene is commonly used as a building block in organic synthesis and as a precursor for the production of various pharmaceuticals, agrochemicals, and other specialty chemicals. It is also known for its ability to undergo various chemical reactions, such as nucleophilic substitution and Suzuki coupling, making it a versatile tool for the development of new molecules in the field of chemistry. Additionally, 1-bromo-4-(2-(methylsulfonyl)ethyl)benzene is considered to be of low toxicity and non-hazardous under normal handling and storage conditions, making it a relatively safe and practical chemical reagent for laboratory and industrial use.

Upstream product

• 4654-39-1 4-bromophenethanol 
• 84913-19-9 4-methylbenzene sulfonic acid 2-(4-bromophenyl)ethyl ester 
• 936727-73-0 (4-bromophenethyl)(methyl)sulfane 
• 512-56-1 trimethyl phosphite 
• 1746-28-7 1-bromo-4-(2-bromoethyl)benzene 

Relevant academic research and scientific papers

General sulfone construction: Via sulfur dioxide surrogate control

A highly efficient one-step synthesis of alkyl-alkyl and aryl-alkyl sulfones with a facile combination of halides, sulfur dioxide surrogates and phosphate esters is described. When thiourea dioxide was employed as a reductive sulfur dioxide surrogate, alkyl-alkyl sulfones were obtained under transition metal free conditions. Aryl-alkyl sulfones were obtained with an extremely low catalytic loading (0.2 mol%) via altering the mask of sulfur dioxide surrogates to sodium dithionite. A phosphate ester was employed as a stable and readily available alkyl source. Notably, this protocol has been applied to the late-stage modification of natural products and bioactive molecules.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.